Zhou et al.318 used CD3 antibody-modified LNPs loaded with IL-6 short hairpin RNA (IL-6 shRNA) and CD19-CAR (based on plasmid DNA) for targeted delivery to CD3+ T cells, which resulted in the downregulation of IL-6 within CAR-T cells and a reduction in cytokine release syndrome (CRS), thereby enhancing the safety profile of leukemia treatment. The gene discussed is IL6; the disease is congenital rubella syndrome.